0512.HK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 05:46):

Stats
Šios dienos apimtis	417 000
Vidutinė apimtis	3.14M
Rinkos kapitalizacija	15.90B
EPS	HKD0 ( 2023-08-10 )
Last Dividend	HKD0.140 ( 2023-06-09 )
Next Dividend	HKD0 ( N/A )
P/E	8.41
ATR14	HKD0.00600 (0.13%)

Tūris Koreliacija

Ilgas: 0.04 (neutral)

Trumpas: -0.22 (neutral)

Signal:(67.793) Neutral

China Grand Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

China Grand Koreliacija - Valiuta/Žaliavos

0.52
( weak )

0.39
( neutral )

0.00
( neutral )

0.53
( weak )

-0.79
( moderate negative )

-0.70
( moderate negative )

China Grand Finansinės ataskaitos

Annual	2023
Pajamos:	HKD10.53B
Bruto pelnas:	HKD6.52B (61.96 %)
EPS:	HKD0.540

FY	2023
Pajamos:	HKD10.53B
Bruto pelnas:	HKD6.52B (61.96 %)
EPS:	HKD0.540

FY	2022
Pajamos:	HKD9.56B
Bruto pelnas:	HKD5.95B (62.24 %)
EPS:	HKD0.590

FY	2021
Pajamos:	HKD8.60B
Bruto pelnas:	HKD5.25B (61.03 %)
EPS:	HKD0.677

Financial Reports:

No articles found.

China Grand Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.140 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

China Grand Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.32 - Stable (26.36%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.0860	2019-06-12
Last Dividend	HKD0.140	2023-06-09
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	HKD0.542	--
Avg. Dividend % Per Year	0.00%	--
Score	3.34	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.32
Div. Directional Score	9.30	--

Next Divdend (Est)
(2025-03-31)

HKD0.162 Estimate 3.09 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.34

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2778.HK	Ex Dividend Junior	2023-09-15	Semi-Annually	0.00%
1449.HK	Ex Dividend Junior	2023-05-24	Insufficient data to determine frequency	0.00%
0533.HK	Ex Dividend Knight	2023-09-05	Semi-Annually	0.00%
6896.HK	Ex Dividend Junior	2023-06-16	Annually	0.00%
1982.HK	Ex Dividend Junior	2023-07-06	Annually	0.00%
1051.HK	Ex Dividend Junior	2023-06-26	Sporadic	0.00%
0124.HK	No Dividend Player	2023-10-06	Sporadic	0.00%
3396.HK	No Dividend Player	2023-07-03	Annually	0.00%
1599.HK	Ex Dividend Junior	2023-05-31	Annually	0.00%
0639.HK	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.179	1.500	6.43	9.64	[0 - 0.5]
returnOnAssetsTTM	0.0835	1.200	7.22	8.66	[0 - 0.3]
returnOnEquityTTM	0.127	1.500	9.70	10.00	[0.1 - 1]
payoutRatioTTM	0.264	-1.000	7.36	-7.36	[0 - 1]
currentRatioTTM	1.224	0.800	8.88	7.10	[1 - 3]
quickRatioTTM	0.843	0.800	9.75	7.80	[0.8 - 2.5]
cashRatioTTM	0.239	1.500	9.78	10.00	[0.2 - 2]
debtRatioTTM	0.148	-1.500	7.53	-10.00	[0 - 0.6]
interestCoverageTTM	12.98	1.000	6.30	6.30	[3 - 30]
operatingCashFlowPerShareTTM	0.636	2.00	9.79	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.494	2.00	9.75	10.00	[0 - 20]
debtEquityRatioTTM	0.221	-1.500	9.12	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.620	1.000	3.01	3.01	[0.2 - 0.8]
operatingProfitMarginTTM	0.253	1.000	6.94	6.94	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.667	1.000	7.41	7.41	[0.2 - 2]
assetTurnoverTTM	0.468	0.800	-0.216	-0.172	[0.5 - 2]
Total Score				12.28

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	8.31	1.000	9.26	0	[1 - 100]
returnOnEquityTTM	0.127	2.50	9.81	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.494	2.00	9.84	10.00	[0 - 30]
dividendYielPercentageTTM	3.14	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.636	2.00	9.79	10.00	[0 - 30]
payoutRatioTTM	0.264	1.500	7.36	-7.36	[0 - 1]
pegRatioTTM	0.171	1.500	-2.19	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.212	1.000	7.21	0	[0.1 - 0.5]
Total Score				6.32

China Grand

Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers pharmaceutical preparations, including cerebro-cardiovascular emergency medicines; respiratory, ophthalmic, anti-infection, and ENT medicines; oncology medicines; and rare disease medicines. It also provides medical devices, such as vascular interventional medical devices comprising paclitaxel releasing coronary balloon dilatation catheters and paclitaxel releasing hemodialysis shunt balloon dilatation catheters; and ophthalmology related devices. In addition, the company offers biotechnology and health products, such as Taurine, amino acid products, steroid products, and bio-pesticides and agricultural antibiotics; and specialized pharmaceutical raw materials and other products, including metronidazole, chloramphenicol, epinephrine, dimethyl sulfate, nitromethane, etc. Further, the company offers agrochemicals, fine chemicals, and chemical medicines; ophthalmic gel and eye drops; steroid hormones active pharmaceutical ingredients and related intermediates; bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. Grand Pharmaceutical Group Limited has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited and changed its name to Grand Pharmaceutical Group Limited in November 2021. Grand Pharmaceutical Group Limited was incorporated in 1995 and is based in Central, Hong Kong.